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Abstract 20 
The HOX genes are a highly conserved family of homeodomain-containing 21 
transcription factors that specify cell identity in early development and, subsequently, 22 
in a number of adult processes including hematopoiesis. The dysregulation of HOX 23 
genes is associated with a number of malignancies including acute myeloid leukemia 24 
(AML) and acute lymphoid leukemia (ALL), where they have been shown to support 25 
the immortalization of leukemic cells both as chimeric partners in fusion genes and 26 
when overexpressed in their wild type form. This review covers our current 27 
understanding of the role of HOX genes in normal hematopoiesis, AML and ALL, 28 
with particular emphasis on the similarities and differences of HOX function in these 29 
contexts, their hematopoietic downstream genes targets and implications for therapy.  30 
Keywords: hematopoiesis, human HOX, murine Hox, AML, ALL. 31 
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1 Introduction 41 
Acute myeloid leukemia (AML) is a heterogeneous group of genetically and 42 
phenotypically aggressive disorders where the differentiation of hematopoietic 43 
progenitor cells is blocked, increasing their self-renewal ability and disturbing the 44 
normal regulation of proliferation1. In the UK, AML is the most frequent acute 45 
leukemia in adults, accounting for 77% of cases. The median age at presentation is 69 46 
years and the male: female ratio is about 5: 4 The disease is commonly classified by 47 
either the French-American-British (FAB) system, or that described by the world 48 
health organization (WHO). The former is based on morphology and maturation stage 49 
and classifies AML into eight groups (M0-M7). The latter is also based on 50 
morphology, but also includes immunophenotyping, genetics and clinical 51 
manifestations and classifies AML into four main groups: AML with recurrent 52 
genetic abnormalities, AML with myelodysplasia-related changes, therapy-related 53 
AML and MDS, or AML that does not fit into any of these groups.  Non-random 54 
chromosomal alterations, such as balanced translocations, monosomies, trisomies, 55 
inversion and deletions have been found in the leukemic cells of almost 55% of AML 56 
patients, and until recently they were considered to be the most crucial prognostic 57 
factors for complete remission (CR), likelihood of relapse, and overall survival3,4. 58 
Recent advances in molecular diagnosis have resulted in both gene alterations 59 
and the dysregulation of specific genes becoming increasingly important as prognostic 60 
elements in AML. This has helped to clarify the numerous heterogeneities of AML 61 
subsets, particularly AML subsets showing normal karyotype (NK-AML)5 and 62 
furthered understanding of the molecular mechanisms of leukemogenesis.  63 
 64 
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1.1 Genetic changes in AML  65 
The origin of AML is associated with two distinct genetic changes, referred to 66 
as Class I and Class II. Class I consists of mutations that enhance proliferation signal 67 
transduction pathways and induce the proliferation of hematopoietic stem cells or 68 
precursors and usually affect kinase signaling pathways, such as FLT3, KIT, 69 
NRAS/KRAS and JAK/STAT mutations. Class I mutations take place late and cause 70 
disease progression. Class II mutations target hematopoietic transcription factor genes 71 
leading to a block in myeloid differentiation and conferring the self-renewal ability of 72 
hematopoietic precursors. These mutations take place early and initiate the AML 73 
disease5-7. One of the most affected and mutated transcription factors are homeobox 74 
(HOX) genes.  75 
1.2 HOX Genes 76 
The HOX genes are a family of homeodomain-containing transcription 77 
factors8, initially characterized in Drosophila as master regulators of trunk and tail 78 
development during embryogenesis9. Duplication of the original HOX gene cluster 79 
has given rise to 39 genes in mammals, separated into four clusters known as A, B, C, 80 
and D9-11. These clusters are located on four different chromosomes, HOXA (7p15), 81 
HOXB (17q21), HOXC (12q13), and HOXD (2q31)12. Ancestors of the original gene 82 
in each of the clusters are known as paralogs, and generally they show a high degree 83 
of sequence similarity as well as functional redundancy (Figure 1)13.  84 
   The arrangement of HOX genes into clusters allows for enhancer sharing 85 
which enables a precise spatial and temporal coordination of expression during 86 
development. The relative regulatory dominance also varies between HOX genes, 87 
giving rise to what is often referred to as a 'HOX code'14, and resulting in the 88 
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following distinctive criteria: (1) Temporal distribution. The expression of HOX genes 89 
starts from the 3' end of the cluster and proceeds stepwise towards the 5' end. (2) 90 
Spatial distribution. The 3’ most member of the cluster is expressed with a more 91 
anterior limit than the next member and each subsequent member has a more posterior 92 
limit of expression resulting in an overlapping series of expression domains. (3) 93 
Posterior prevalence.  In each individual cluster, the function of the posterior gene 94 
products is dominant over the more anterior genes13.  95 
1.3 HOX Cofactors 96 
DNA binding site studies suggest that HOX proteins have relatively limited 97 
selectivity and specificity, and they need cofactor interactions in order to increase 98 
both15-17. The most important HOX-cofactors are the three amino acid loop extension 99 
(TALE) proteins, which comprise the pre B cell leukemia (PBX) and myeloid 100 
ectropic insertion site (MEIS) families16,17. These cofactors play crucial roles in 101 
development and hematopoiesis18. For example, Pbx1 null mice die during the 102 
embryonic stage as a result of severe hematopoietic defects19, and Meis1 deficient 103 
mice fail to generate megakaryocytes, exhibit severe hemorrhaging and likewise die 104 
during the embryonic stage20. In zebrafish, Meis1 and Pbx contribute to the 105 
production of erythropoietic cells and the inhibition of myelopoiesis21. Generally, Hox 106 
proteins 1-10 bind to Pbx122, whereas Hox proteins 9-13 bind to Meis123. 107 
2 HOX genes in hematopoiesis 108 
HOX genes are expressed in hematopoietic stem cells and progenitors in a manner 109 
reminiscent of their expression in early development, with lineage and differentiation 110 
stage- restricted patterns. Thus, for example, HOXB3, HOXB4, and HOXA9 are highly 111 
expressed in uncommitted hematopoietic cells, whilst HOXB8 and HOXA10 are 112 
  6
expressed in myeloid committed cells. The different HOX clusters also have specific 113 
patterns of lineage restricted expression, whereby HOXA genes are expressed in 114 
myeloid cells, HOXB genes in erythroid cells, and HOXC genes in lymphoid cells. 115 
Intriguingly, the HOXD genes are not expressed in hematopoiesis despite having 116 
similar regulatory regions to the other clusters24-26. Different mammalian CD34+ cell 117 
subpopulations express at least 22 of the 39 HOX genes27. Anterior ''3' end'' HOX 118 
genes (HOX1-6) are highly expressed in the most primitive HSCs. Subsequently, the 119 
anterior HOX genes are down regulated, and posterior "5' end'' HOX genes are 120 
expressed during commitment28. HOX genes are highly expressed in the most 121 
primitive hematopoietic stem cells and progenitors, while their expression is almost 122 
absent in CD34- cells, which are considered differentiated bone marrow cells26,28.  The 123 
analysis of HOX gene expression in human multipotent stem cells and T-cell 124 
precursors showed that HOXA genes are prominently expressed during T-cell 125 
development, in particular the Abd-HOXA genes including HOXA7-HOXA11, with 126 
only HOXB3 and HOXC3 expressed from the other HOX clusters29.  127 
2.1 Gain of function studies 128 
The function of HOX genes in normal hematopoiesis has been widely studied 129 
using gene expression analysis and knock in or knock out studies in hematopoietic 130 
stem cells and early hematopoietic progenitors (Table 1). Generally the 131 
overexpression of a HOX gene leads to an expansion of stem and progenitor cell 132 
populations together with a block on differentiation. Notable examples of this include 133 
the overexpression of murine Hoxb6, which resulted in the expansion of murine HSCs 134 
and myeloid precursors, together with the inhibition of erythropoiesis and 135 
lymphopoiesis30, and overexpression of murine Hoxb3 that resulted in several 136 
hematological abnormalities, such as a block of B and T cell differentiation as well as 137 
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a delay in myeloid precursor proliferation31. Overexpression of human HOXC4 138 
resulted in expansion of early and committed myeloid and erythroid progenitors32, and 139 
knock in of human HOXA5 caused an increase in the number of myeloid progenitors 140 
and blocked erythroid differentiation33,34. Likewise, overexpression of HOXA10 in 141 
human cord blood or fetal liver CD34+ hematopoietic progenitors resulted in a 142 
significant production of blast cells and myelopoiesis concomitant with a complete 143 
block of erythroid differentiation and a severe reduction in B-cell development35. 144 
Other HOX genes are required for the maintenance of progenitor or stem cell status 145 
and promote their proliferation, especially HOXA9 and HOXB4. The former is the 146 
most preferentially expressed HOX gene in human CD34+ hematopoietic stem cells 147 
and early hematopoietic progenitors and is subsequently down regulated during 148 
differentiation. Murine Hoxa9 overexpression enhances HSC expansion and myeloid 149 
progenitor proliferation and, with a long latency, leads to leukemia36,37. In contrast to 150 
myeloid progenitors, Hoxa9 overexpression resulted in a partial inhibition of pre-B 151 
cell differentiation, but did not affect T-cell development37. Hoxb4 is also highly 152 
expressed in hematopoietic stem cells and down regulated during differentiation26,28. 153 
Its overexpression in murine and human cell lines results in a remarkable expansion 154 
of HSCs in vivo and in vitro without resulting in leukemia or lineage disturbances38,39. 155 
Indeed, the self-renewal ability of Hoxb4-transduced HSCs is 20-50 fold greater than 156 
untreated cells, and can be increased still further by knocking down Pbx140,41.  157 
2.2 Loss of function studies  158 
In addition to the knock-in and overexpression approaches described above, 159 
knock down and deletion studies in murine models and cell lines have also been used 160 
to evaluate the role of HOX genes in hematopoiesis. However, due to the functional 161 
redundancy of HOX genes, the results of knock down assays are sometimes difficult 162 
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to interpret and do not always reflect the findings of studies where the gene has been 163 
overexpressed. For example, it has been found that Hoxb4 null mice exhibit a 164 
significant reduction in size and cellularity of hematopoietic organs, such as spleen 165 
and liver, and a slight decrease in HSCs and hematopoietic progenitor number without 166 
a significant disturbance of lineage commitment42,43. Likewise, Hoxb3 null mice 167 
display a notable reduction in B cell progenitors, and a reduction in bone marrow 168 
cellularity, but no significant reduction in B cell numbers in the spleen44.   Hoxb3/b4 -169 
/- mice have a greater reduction in HSCs and hematopoietic progenitors, yet no 170 
difference in hematopoietic cell commitment45. Using quantitative PCR, it has been 171 
demonstrated that fetal liver cells (c-Kit+) of Hoxb4 null mice expressed other Hoxb 172 
genes to a significantly higher level than control cells43.  173 
Bijl and colleagues (2006) found that an individual loss of Hoxb4 or even the 174 
complete loss of the Hoxb cluster (b1-b9) did not affect the ability of murine fetal 175 
liver HSCs to self-renew. The repopulation and differentiation potential were retained, 176 
compared to wild-type control cells. Thus, the Hoxb cluster may not be necessary for 177 
hematopoiesis, with members of the other Hox clusters presumably having largely 178 
duplicate roles. Analysis of Hox gene expression in fetal liver cells (c-Kit+ Hoxb1-179 
Hoxb9-/-), revealed genetic interactions between members of the Hoxa, b and c 180 
clusters, whereby these cells exhibited down regulation of all Hoxa genes, except 181 
Hoxa13,  and up regulation of Hoxc4, Hoxc9 and Hoxc11, also suggesting  functional 182 
redundancy and complex genetic interactions between Hox genes.   183 
An exception to the general prevalence of functional redundancy amongst the 184 
HOX gene family is HOXA9, the most highly expressed HOX family member in 185 
HSCs.  Hoxa9-/- mice showed significant deficiencies in myeloid and lymphoid cells 186 
concomitant with a significant defect in repopulating ability. These deficiencies 187 
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include common myeloid progenitors (CMPs), granulocyte/monocyte precursors 188 
(GMPs), common lymphoid precursors (CLPs) and lymphoid precursors (pro- and 189 
pre-B cells, pro-T cells)47. There is also a corresponding reduction in spleen 190 
cellularity and size. Notably, compared to the entire cluster b deficient fetal liver 191 
HSCs, Hoxa9-/- fetal liver HSCs exhibited a more dramatic defect in repopulating 192 
ability43,47, and HSCs from Hoxa9/b3/b4 null mice had the same repopulating ability 193 
as those from Hoxa9 null mice47. Gene knock-down studies have revealed that some 194 
additional HOX genes are also essential in normal hematopoiesis. Knock down of 195 
HOXA5 led to an increase in erythroid progenitors and a reduction in the number of 196 
myelomonocytic cells33,34, and Hoxa7 null mice showed a reduction in 197 
megakaryocytic/erythroid progenitors (MEP) as well as reticulocytosis and 198 
thrombocytopenia46. Knock out of Hoxb6 resulted in an increase in early erythroid 199 
progenitors in murine bone marrow and fetal liver cells48. Likewise, Hoxc3-/- mice 200 
showed a reduction in late erythroid progenitors without affecting the 201 
hemoglobinization size49, and Hoxc8 deficient mice showed a significant reduction in 202 
erythroid, granulocyte and macrophage colony formation potential50. 203 
 204 
2.3 Upstream regulators of HOX genes 205 
Knock out models of HOX gene upstream regulators have helped to define 206 
their role in normal hematopoiesis. Regulators include transcriptional activators such 207 
as mixed lineage, myeloid lymphoid, leukemia (MLL), and a family of caudal-type 208 
homeobox transcription factors (CDX1, CDX2, and CDX4). The existence of HOX 209 
genes in clusters makes them particularly sensitive to changes in chromosomal 210 
organization, and repressors of HOX transcription include genes that mediate this 211 
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process, most notably members of the polycomb group (PcG)51. These regulators play 212 
crucial roles in normal development and hematopoiesis through the regulation of 213 
HOX genes. A number of studies demonstrated that Mll deficient embryonic bodies 214 
(EB) and Mll conditional knockout mice showed a dramatic reduction in HSCs and 215 
hematopoietic progenitors. Additionally, these EB and the mice exhibited greatly 216 
reduced expression of a number of Hox genes including Hoxa7, Hoxa9, Hoxa10 and 217 
other Hoxb and Hoxc genes52,53. Likewise, Cdx compound deficient zebrafish and 218 
murine ESCs showed dysregulation of the embryonic hematopoietic progenitors as 219 
well as impaired expression of Hox genes54,55.  However, it has been shown that Cdxs 220 
are not essential for normal hematopoiesis in adult mice. For example, Cdx4 deficient 221 
mice showed minimal hematopoietic defects though it is highly expressed in wild type 222 
myeloid progenitor cells56. In addition, human CDX2 is not expressed in normal 223 
HSCs, or in myeloid, B-cell, or T-cell progenitors57-59. 224 
2.4 HOX downstream target genes in hematopoietic cells 225 
The mechanism by which HOX genes regulate hematopoiesis is not yet fully 226 
understood. However, genome wide analyses after experimentally induced changes in 227 
HOX gene expression have identified some potential downstream targets. Amongst 228 
these are the HOX genes themselves, some of which have been shown to auto-activate 229 
their own expression or to cross regulate their neighbours, or their co-factors. HOXA9, 230 
HOXA10 and HOXB4 are the most comprehensively studied genes in this respect 231 
because of their key roles in normal hematopoiesis and leukemia. It is particularly 232 
noteworthy that HOXA9 positively regulates the transcription of other HOX genes 233 
including HOXA7 and HOXA10 and its cofactors PBX3 and MEIS160. A summary of 234 
HOX downstream target genes is presented in table 2.   235 
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As described above, HOXA9 is a key regulator of hematopoiesis and behaves 236 
as an oncogene in leukemia. It is therefore unsurprising that it activates the 237 
transcription of genes known to regulate cell proliferation and survival. For example, 238 
Hoxa9 directly activates the Pim1 gene, the product of which enhances proliferation 239 
by activating c-Myb, and also exerts an anti-apoptotic effect by phosphorylating and 240 
inactivating the BAD protein61,62. C-Myb has also been identified as an indirect 241 
transcriptional target of Hoxa9-Meis1 that mediates transformation in Mll-Enl 242 
leukemia63. Other HOXA9 targets include the oncogene ID2 which is up regulated, 243 
and BIM, which encodes an apoptotic factor and is down regulated64. HOXA9 also 244 
activates the CYBB gene, which encodes Gp91phox (a phagocyte respiratory burst 245 
oxidase protein) and is expressed in differentiated myeloid cells65. In mice, Hoxa9 has 246 
been shown to directly activate the transcription of the Flt3 gene, which is associated 247 
with an unfavourable prognosis of AML66, and it also regulates its own cofactor, 248 
Meis1, through binding to Meis1 upstream regulator genes cerb1 and pknox167. More 249 
proliferative genes have been recently identified as downstream targets for Hoxa9 250 
including Camk2d, Cdk6, Erg, Etv6, Flt3, Foxp1, Gfi1, Kit, Lck, Lmo2, Myb and 251 
Sox468. In the same study, it was shown that Hoxa9 down regulates differentiation and 252 
inflammation genes including Ifit1, Tlr4, Ccl3, Ccl4, Csf2rb, Ifngr1, Runx1, Cd28 and 253 
Cd33. The fusion protein NUP98-HOXA9 has been found to stimulate the 254 
proliferation of HSCs by activating the expression of other homeobox genes including 255 
HOXA9, HOXA7, MEIS1 and PBX3. It also up regulates a number of leukemogenic 256 
transcription factors including EVI1 and MEF2C, and receptor tyrosine kinases 257 
including FLT3 and KIT69. 258 
It is also of note that there are both overlapping opposing functions between 259 
the closely related HOXA9 and HOXA10 transcription factors. For example, in a 260 
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similar manner to Hoxa9, Hoxa10 activates the expression of proliferative genes that 261 
result in myeloid progenitor expansion such as Itgb3, Hif, Tgfβ2 and Fgf2 by direct 262 
binding to their promoters70-73. HOXA10 also activates the transcription of anti-263 
apoptotic genes such as DUSP4, which encodes mitogen-activated protein kinase 2 264 
(MPK2). MPK2 in turn prevents cell death by down regulating JNK and p36 Map-265 
kinase74. Hoxa10 decreases erythroid differentiation and megakaryopoiesis by 266 
activating Hoxa5 and inactivating Gata-1, respectively70, and it also induces Cdx4 267 
expression in myeloid cells75. 268 
Unlike HOXA9, HOXA10 can also exert anti-proliferative effects. For 269 
example, in cooperation with its trimeric cofactors, HOXA10 induces P21 270 
transcription leading to cell cycle arrest and differentiation76. It also represses CYBB 271 
transcription77, thereby acting in an opposing manner to HOXA9. In a fusion form 272 
with Nup98, Hoxa10 activates more than 400 genes including the self-renewal genes 273 
Flt3, Prnp, Hlf, Jag278.   274 
Many HOXB4 target genes have also been identified in three recent studies79-275 
81. Overexpression of Hoxb4 resulted in transcriptional up regulation of Meis1, Dntt, 276 
Hlf, Sox4 and Runx2, whilst it down regulated the transcription of lymphoid specific 277 
genes, such as B220, and myeloid specific genes, such as Hmbs79. Some HOXB4 278 
targets seem to vary in a context dependent manner, for example it has been found to 279 
down regulate the transcription of C-MYC in the HL-60 cell line leading to cell 280 
differentiation82, whilst it activates c-Myc transcription in murine BM cells83. As with 281 
HOXA9, Hoxb4 activates the transcription of its neighbouring genes, Hoxb2, Hoxb3 282 
and Hoxb542. Hoxb4 also activates the AP-1 complex members Fra-1 and Jun-B 283 
which leads in turn to an increase in the level of cyclin-D1 and a decrease in the level 284 
of c-Fos transcription, thereby increasing the proliferation capacity of HSCs84.  285 
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3 The role of HOX genes in acute leukemia 286 
Numerous studies have now shown that HOX genes can promote the 287 
development of AML by forming chimeric fusions with other genes, but more recent 288 
work has also shown that their miss-expression, in particular their overexpression, is 289 
also important in the formation of malignancy. 290 
3.1 HOX fusion proteins 291 
One of the most frequent fusion partners for HOX genes is nucleoporin 98 292 
(NUP98), a member of the nuclear pore family (Figure 2). It is localized in the 293 
nuclear membrane and functions as a selective transporter for RNA and proteins 294 
between the nucleus and cytoplasm. NUP98-HOX fusion proteins have been reported 295 
in AML and other leukemias. In AML, NUP98-HOXA9 is associated with a 296 
t(7;11)(p15;p15) translocation85,86. There are eight other HOX genes that can be fused 297 
with NUP98, including HOXA11 and HOXA1387,88, HOXD11 and HOXD1389,90, and 298 
HOXC1391. Thus only the 5’ most members of each HOX complex have been 299 
documented to be fused with NUP98 in AML. However, Hoxb3 has been shown to be 300 
a potential leukemogenic partner with Nup9892, suggesting that the ability to be a 301 
fusion NUP98 partner is not limited to the 5’ most HOX genes. 302 
Nup98-Hox fusion proteins result in AML with a long latency, around 11-12 303 
months. However, this latency can be reduced to two months by co-overexpression of 304 
the Hox cofactor Meis1 and the receptor tyrosine kinase Flt393-95. FLT3 has an 305 
essential role in the regulation of early hematopoietic progenitors growth, and causes 306 
increased and uncontrolled self-renewal of these cells through a FLT3 ligand-307 
independent pathway96. 308 
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3.2 HOX overexpression in AML 309 
HOX genes may also be indirectly involved in AML through chromosomal 310 
rearrangements that involve their upstream regulators, such as MLL. MLL fusion 311 
proteins constitute about 10% of therapy related AML (t-AML) and 3% of de novo 312 
AML97. There are more than 64 translocation partner genes (TPG) that fuse with the 313 
MLL N-terminus98. Normally, Mll positively regulates the transcription of Hox genes 314 
by maintaining their expression through direct binding to a proximal promoter 315 
region99. MLL fusion proteins activate HOX gene transcription more efficiently than 316 
MLL alone97, especially the 5’ most members of the HOXA cluster, together with 317 
their co-activator MEIS1. As a consequence myeloid differentiation is blocked and 318 
proliferation is enhanced. Consistent with this proposed mechanism, it has been 319 
reported that MLL-AF9, like NUP98-HOXA9, leads to a block in erythroid/myeloid 320 
maturation and to erythroid hyperplasia100, and the Mll-Enl fusion protein requires 321 
Hoxa7 and Hoxa9 for efficient immortalization of myeloid precursor cells101. 322 
Conversely, a number of studies demonstrated that the expression of HOXA genes is 323 
not crucial for MLL leukemogenesis, yet their expression affects disease phenotype. 324 
For instance, Hoxa7 and Hoxa9 influence AML latency and phenotype; yet they are 325 
not essential to initiate Mll-Gas7 mediated leukemogenesis46. Furthermore, 326 
suppression of HOXA9 expression in cells with a chimeric MLL-AF9 gene reduces 327 
the survival of leukemic cells and changes the disease phenotype, but it does not 328 
affect AML initiation60.  329 
The dysregulation of another regulator of HOX genes, the CDX gene family, 330 
has also been shown to drive the development of AML. CDX2 is expressed in the 331 
majority of AML cases (90%), but not in normal adult hematopoiesis, and Cdx2 332 
elevated expression leads to AML with only a short latency period57. In contrast, the 333 
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closely related CDX4 gene is expressed in 25% of AML cases, and in normal adult 334 
hematopoiesis, and Cdx4 overexpression in murine whole bone marrow results in 335 
AML but only with a long latency period102. This latency can be accelerated in mice 336 
through cooperation of Meis1 which results in the overexpression of a number of Hox 337 
genes including Hoxa6, Hoxa7, Hoxa9, Hoxb4, Hoxb8 and Hoxc6103. Cdx2 expression 338 
alone is sufficient to drive the up regulation of a related set of HOX genes58, 339 
demonstrating the importance of the Cdx family in the dysregulation of Hox genes 340 
during AML.  341 
 The dysregulation of HOX gene expression is also associated with the 342 
nucleophosmin 1 (NPM1) mutation. NPM1 is a chaperone protein that shuttles 343 
between the nucleus and cytoplasm, although its predominant localization is in the 344 
nucleus104. NPM1 has a crucial role in several biological processes, such as ribosome 345 
biogenesis, genomic stability and cell cycle progression. In adult AML, NPM1 346 
mutation is the most common genetic aberration, reported in about 35% of all adult 347 
AML and approximately in 45% to 55% of normal karyotype AML (NK-AML)105-107. 348 
In pediatric AML, NPM1 mutations are significantly less common, occurring in 8-349 
10% of cases, and in about a quarter of normal karyotype cases108,109. The relocation 350 
of NPM1 into the cytoplasm (NPMc+) occurs only in AML110. This relocation causes 351 
up regulation of a number of HOX genes, some of which are similar to those seen in 352 
AML initiated by a MLL chimeric gene fusion, whilst some are distinct. Thus for 353 
example HOXA4, HOXA6, HOXA7, HOXA9, HOXB9 and MEIS1 are overexpressed 354 
in both contexts, whilst HOXB2, HOXB3, HOXB5, HOXB6 and HOXD4 are up 355 
regulated in NPMc+ AML only111. It has been reported that activation of a humanized 356 
Npm1 allele led to overexpression of Hoxa5, Hoxa7, Hoxa9 and Hoxa10, induction of 357 
HSC self-renewal and the expansion of myelopoiesis112. The exact mechanism of the 358 
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association between the NPM1 mutation and the up regulation of HOX genes is still 359 
unclear. A possible explanation is that NPM1 directly disturbs the expression of HOX 360 
genes, or alternatively, that NPM1 mutations arrest the differentiation of early 361 
hematopoietic progenitors in which HOX expression is up regulated104.  362 
 363 
3.3 HOX gene dysregulation in Acute Lymphoid Leukemia (ALL) 364 
The dysregulation of HOX genes has also been reported in ALL including both 365 
B- and T-precursor ALL (B- ALL and T-ALL), especially when MLL translocations 366 
(MLL-t ALL) are involved. For example, human HOXA9, HOXA10 and HOXC6, and 367 
their cofactor MEIS1 were up regulated in both MLL-ENL T-ALL and MLL B-368 
ALL113. Human HOXA9 and MEIS1, and murine Hoxa5, Hoxa9 and Meis1 were 369 
likewise up regulated in MLL-AF4 B-ALL114,115. A common signature of MLL 370 
rearrangements in AML and ALL is the overexpression of HOXA genes including 371 
HOXA3, HOXA5, HOXA7, HOXA9 and HOXA10116. Additionally, HOX genes can be 372 
involved in T-ALL through other translocations such as CALM-AF10 T-ALL where 373 
human HOXA5, HOXA9, HOXA10 and MEIS1 are overexpressed117. HOXA proteins 374 
can also form chimeric fusion proteins with T cell receptor (HOXA-TCR) in T-ALL 375 
which results in the global overexpression of HOXA genes118,119. Surprisingly, the 376 
aberrant expression of CDX2 in ALL, an upstream regulator of HOX genes, is not 377 
correlated with HOX gene dysregulation120.  378 
3.4 HOX genes as prognostic markers 379 
HOX gene expression has become an important prognostic factor in AML. 380 
Overexpression of HOX genes is associated with an intermediate/ unfavorable 381 
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cytogenetic subset of AML.  For example, among 6817 genes that have been 382 
investigated in AML patients, the single gene correlated with the worst outcome and 383 
relapse of disease as well as short survival was HOXA9121.  Correspondingly, low 384 
HOXA9 expression was found to correlate with the best outcome and response to 385 
therapy122. It is also noteworthy that low expression of HOXA4 and MEIS1 are also 386 
favorable predictors for AML patient outcome123. The global levels of HOX 387 
expression also seem to reflect the outcome of disease, possibly reflecting the 388 
functional redundancy exhibited by many of the HOX genes. Thus the highest levels 389 
of HOX genes are seen in FLT3 mutation cases, which have unfavorable outcomes, 390 
and generally the HOX genes are expressed only at a very low level in favorable 391 
subsets of AML.  392 
Future directions 393 
Although recent work has established the importance of HOX genes in the 394 
development of AML, it is still not clear exactly what the functions of these genes are 395 
beyond a general inhibition of differentiation and an increase in cell proliferation. 396 
This lack of precise mechanistic knowledge for individual HOX genes may be due to 397 
the functional redundancy showed by many members of this family, making the 398 
knock-down of single HOX genes generally difficult to interpret, and it may also help 399 
to explain the contrast in gene knock-in and knock-out results. In myeloma and some 400 
solid malignancies this has been addressed by targeting the HOX genes as a group by 401 
antagonizing their interactions with the PBX co-factor using the peptide inhibitor 402 
HXR9124-128. A similar approach may be useful in AML for addressing redundant 403 
functions of HOX genes. HXR9 is cytotoxic to cells, predominantly through the 404 
induction of apoptosis, which in turn depends upon a rapid increase in expression of 405 
cFos124-129. It seems likely that AML would also be sensitive to killing by HXR9, and 406 
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indeed it may be that the HOX genes could represent a useful therapeutic target, 407 
especially in AMLs that show high levels of HOX expression and a correspondingly 408 
poor prognosis. 409 
 410 
Acknowledgement 411 
Raed Alharbi gratefully acknowledges the support of Albaha University. 412 
 413 
 414 
 415 
 416 
 417 
 418 
 419 
 420 
 421 
 422 
 423 
 424 
 425 
  19
References 426 
1) Frohling S, Scholl C, Gilliland DG, Levine RL. Genetics of myeloid 427 
malignancies: pathogenetic and clinical implications. J Clin Oncol 2005; 23: 428 
6285-6295. 429 
2) Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of 430 
haematological malignancy by sub-type: a report from the Haematological 431 
Malignancy Research Network. Br J Cancer 2011; 105: 1684-1692. 432 
3) Estey E, Döhner H. Acute myeloid leukaemia. The Lancet  2006; 368: 1894-1907. 433 
4)  Mrózek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD. Clinical 434 
relevance of mutations and gene-expression changes in adult acute myeloid 435 
leukemia with normal cytogenetics: are we ready for a prognostically 436 
prioritized molecular classification? Blood  2007; 109: 431-448. 437 
5) Dohner K, Dohner H. Molecular characterization of acute myeloid leukemia. 438 
Haematologica  2008; 93: 976-982. 439 
6) Renneville A, Roumier C, Biggio V, Nibourel O, Boissel N, Fenaux P et al. 440 
Cooperating gene mutations in acute myeloid leukemia: a review of the 441 
literature. Leukemia  2008; 22: 915-931. 442 
7) Betz BL, Hess JL. Acute Myeloid Leukemia Diagnosis in the 21st Century. 443 
Archives of Pathology & Laboratory Medicine  2010; 134: 1427-1433. 444 
8) Garcia-Fernandez J. Hox, ParaHox, ProtoHox: facts and guesses. Heredity  2004; 445 
94: 145-152. 446 
  20
9) Shah N, Sukumar S. The Hox genes and their roles in oncogenesis. Nat Rev Cancer 447 
2010; 10: 361-371. 448 
10)  Abramovich C, Pineault N, Ohta H, Humphries RK. Hox Genes: From Leukemia 449 
to Hematopoietic Stem Cell Expansion. Annals of the New York Academy of 450 
Sciences 2005; 1044: 109-116. 451 
11) Amores A, Force A, Yan YL, Joly L, Amemiya C, Fritz A et al. Zebrafish hox 452 
clusters and vertebrate genome evolution. Science 1998; 282: 1711-1714. 453 
12) Rice KL, Licht JD. HOX deregulation in acute myeloid leukemia. The Journal of 454 
Clinical Investigation 2007; 117: 865-868. 455 
13) He H, Hua X, Yan J. Epigenetic regulations in hematopoietic Hox code. 456 
Oncogene 2011; 30: 379-388. 457 
14) Knittel T, Kessel M, Kim MH, Gruss P. A conserved enhancer of the human and 458 
murine Hoxa-7 gene specifies the anterior boundary of expression during 459 
embryonal development. Development 1995; 121: 1077-1088. 460 
15)  Phelan M, Rambaldi I, Featherstone M. Cooperative interactions between HOX 461 
and PBX proteins mediated by a conserved peptide motif. Mol Cell Biol 1995; 462 
15: 3989-3997. 463 
16) Moens CB, Selleri L. Hox cofactors in vertebrate development. Developmental 464 
Biology 2006; 291: 193-206. 465 
  21
17) Mann RS, Lelli KM, Joshi R. Chapter 3 Hox Specificity: Unique Roles for 466 
Cofactors and Collaborators. Current Topics in Developmental Biology 2009 467 
Academic Press. 468 
18) Thorsteinsdottir U, Kroon E, Jerome L, Blasi F, Sauvageau G. Defining Roles for 469 
HOX and MEIS1 Genes in Induction of Acute Myeloid Leukemia. Mol Cell 470 
Biol 2001; 21: 224-234. 471 
19) Dimartino JF, Selleri L, Traver D, Firpo MT, Rhee J, Warnke R, et al. The Hox 472 
cofactor and proto-oncogene Pbx1 is required for maintenance of definitive 473 
hematopoiesis in the fetal liver. Blood  2001; 98: 618-626. 474 
20) Hisa T, Spence SE, Rachel RA, Fujita M, Nakamura T, Ward JM, et al. 475 
Hematopoietic, angiogenic and eye defects in Meis1 mutant animals. EMBO J 476 
2004; 23: 450-459. 477 
21) Pillay LM, Forrester AM, Erickson T, Berman JN, Waskiewicz AJ. The Hox 478 
cofactors Meis1 and Pbx act upstream of gata1 to regulate primitive 479 
hematopoiesis. Developmental Biology 2010; 340: 306-317. 480 
22) Shen WF, Chang CP, Rozenfeld S, Sauvageau G, Humphries RK, Lu M et al. 481 
Hox Homeodomain Proteins Exhibit Selective Complex Stabilities with Pbx 482 
and DNA. Nucleic Acids Research 1996; 24: 898-906. 483 
23) Shen W, Montgomery J, Rozenfeld S, Moskow J, Lawrence H, Buchberg AC et 484 
al.  AbdB-like Hox proteins stabilize DNA binding by the Meis1 485 
homeodomain proteins. Mol Cell Biol 1997; 17: 6448-6458. 486 
  22
24)  Giampaolo A, Sterpetti P, Bulgarini D, Samoggia P, Pelosi E, Valtieri M et al. 487 
Key functional role and lineage-specific expression of selected HOXB genes 488 
in purified hematopoietic progenitor differentiation. Blood  1994; 84: 3637-489 
3647. 490 
25) Kawagoe H, Humphries RK, Blair A, Sutherland HJ, Hogge DE. Expression of 491 
HOX genes, HOX cofactors, and MLL in phenotypically and functionally 492 
defined subpopulations of leukemic and normal human hematopoietic cells. 493 
Leukemia 1999; 13: 687-698. 494 
26) Pineault N, Helgason CD, Lawrence HJ, Humphries RK. Differential expression 495 
of Hox, Meis1, and Pbx1 genes in primitive cells throughout murine 496 
hematopoietic ontogeny. Experimental Hematology 2002; 30: 49-57. 497 
27) Grier DG, Thompson A, Kwasniewska A, Mcgonigle GJ, Halliday HL, Lappin, 498 
TR. The pathophysiology of HOX genes and their role in cancer. Journal of 499 
Pathology 2005; 205: 154-171. 500 
28) Sauvageau G, Lansdorp PM, Eaves CJ, Hogge DE, Dragowska WH, Reid DS, et 501 
al. Differential Expression of Homeobox Genes in Functionally Distinct 502 
CD34+ Subpopulations of Human Bone Marrow Cells. Proceedings of the 503 
National Academy of Sciences of the United States of America  1994; 91: 504 
12223-12227. 505 
29) Taghon T, Thys K, De Smedt M, Weerkamp F, Staal FJT, Plum J et al. 506 
Homeobox gene expression profile in human hematopoietic multipotent stem 507 
  23
cells and T-cell progenitors: implications for human T-cell development. 508 
Leukemia 2003; 17: 1157-1163. 509 
30) Fischbach NA, Rozenfeld S, Shen W, Fong S, Chrobak D, Ginzinger D, et al. 510 
HOXB6 overexpression in murine bone marrow immortalizes a 511 
myelomonocytic precursor in vitro and causes hematopoietic stem cell 512 
expansion and acute myeloid leukemia in vivo. Blood  2005; 105: 1456-1466. 513 
31) Sauvageau G, Thorsteinsdottir U, Hough MR, Hugo P, Lawrence HJ, Largman C. 514 
et al. Overexpression of HOXB3 in hematopoietic cells causes defective 515 
lymphoid development and progressive myeloproliferation. Immunity 1997; 6: 516 
13-22. 517 
32) Daga A, Podesta M, Capra MC, Piaggio G, Frassoni F, Corte G. The retroviral 518 
transduction of HOXC4 into human CD34+ cells induces an in vitro 519 
expansion of clonogenic and early progenitors. Experimental Hematology 520 
2000; 28: 569-574. 521 
33)  Crooks GM, Fuller J, Petersen D, Izadi P, Malik P, Pattengale PK et al. 522 
Constitutive HOXA5 Expression Inhibits Erythropoiesis and Increases 523 
Myelopoiesis From Human Hematopoietic Progenitors. Blood  1999; 94: 519-524 
528. 525 
34) Fuller JF, Mcadara J, Yaron Y, Sakaguchi M, Fraser  JK, Gasson JC. 526 
Characterization of HOX Gene Expression During Myelopoiesis: Role of 527 
HOX A5 in Lineage Commitment and Maturation. Blood 1999; 93: 3391-528 
3400. 529 
  24
35) Buske C, Feuring-Buske M, Antonchuk J, Rosten P, Hogge DE, Eaves CJ et al. 530 
Overexpression of HOXA10 perturbs human lymphomyelopoiesis in vitro and 531 
in vivo. Blood  2001; 97: 2286-2292. 532 
36)  Kroon E, Krosl J, Thorsteinsdottir U, Baban S, Buchberg AM, Sauvageau G. 533 
Hoxa9 transforms primary bone marrow cells through specific collaboration 534 
with Meis1a but not Pbx1b. EMBO J 1998; 17: 3714-3725. 535 
37) Thorsteinsdottir U, Mamo A, Kroon E, Jerome L, Bijl J, Lawrence HJ et al. 536 
Overexpression of the myeloid leukemia–associatedHoxa9 gene in bone 537 
marrow cells induces stem cell expansion. Blood 2002; 99: 121-129. 538 
38)  Sauvageau G, Thorsteinsdottir U, Eaves CJ, Lawrence HJ, Largman C, Lansdorp, 539 
PM et al. Overexpression of HOXB4 in hematopoietic cells causes the 540 
selective expansion of more primitive populations in vitro and in vivo. Genes 541 
& Development 1995; 9: 1753-1765. 542 
39) Amsellem S, Pflumio F, Bardinet D, Izac B, Charneau P, Romeo PH et al. Ex 543 
vivo expansion of human hematopoietic stem cells by direct delivery of the 544 
HOXB4 homeoprotein. Nat Med 2003; 9: 1423-1427. 545 
40)  Krosl J, Beslu N, Mayotte N, Humphries RK, Sauvageau G. The Competitive 546 
Nature of HOXB4-Transduced HSC Is Limited by PBX1: The Generation of 547 
Ultra-Competitive Stem Cells Retaining Full Differentiation Potential. 548 
Immunity 2003; 18: 561-571. 549 
  25
41) Cellot S, Krosl J, Chagraoui J, Meloche S, Humphries RK, Sauvageau G. 550 
Sustained in vitro trigger of self-renewal divisions in Hoxb4(hi)Pbx1(lo) 551 
hematopoietic stem cells. Experimental Hematology 2007; 35: 802-816. 552 
42)  Brun ACM, Björnsson JM, Magnusson M, Larsson N, Leveén P, Ehinger M, et 553 
al.. Hoxb4-deficient mice undergo normal hematopoietic development but 554 
exhibit a mild proliferation defect in hematopoietic stem cells. Blood  2004; 555 
103: 4126-4133. 556 
43) Bijl J, Thompson A, Ramirez-Solis R, Krosl J, Grier DG. Lawrence HJ et al.. 557 
Analysis of HSC activity and compensatory Hox gene expression profile in 558 
Hoxb cluster mutant fetal liver cells. Blood 2006; 108: 116-122. 559 
44) Ko KH, Kwan Lam QL, Zhang M, Yen Wong CK, Chun Lo CK, Kahmeyer-560 
Gabbe M et al.  Hoxb3 deficiency impairs B lymphopoiesis in mouse bone 561 
marrow. Experimental Hematology 2007; 35: 465-475. 562 
45) Bjornsson JM, Larsson N, Brun ACM, Magnusson M, Andersson E, Lundstrom P 563 
et al. Reduced Proliferative Capacity of Hematopoietic Stem Cells Deficient in 564 
Hoxb3 and Hoxb4. Mol. Cell. Biol  2003; 23: 3872-3883. 565 
46) So CW, Karsunky H, Wong P, Weissman IL, Cleary ML. Leukemic 566 
transformation of hematopoietic progenitors by MLL-GAS7 in the absence of 567 
Hoxa7 or Hoxa9. Blood 2004; 103: 3192-3199. 568 
  26
47) Magnusson M, Brun ACM, Lawrence HJ, Karlsson S. Hoxa9/hoxb3/hoxb4 569 
compound null mice display severe hematopoietic defects. Experimental 570 
Hematology 2007a; 35: 1421.e1-1421.e9. 571 
48) Kappen C. Disruption of the homeobox gene Hoxb-6 in mice results in increased 572 
numbers of early erythrocyte progenitors. American Journal of Hematology, 573 
2000; 65: 111-118. 574 
49) Takeshita K, Bollekens JA, Hijiya N, Ratajczak M, Ruddle FH, Gewirtz AM. A 575 
homeobox gene of the antennapedia class is required for human adult 576 
erythropoiesis. Proceedings of the National Academy of Sciences of the United 577 
States of America, 1993; 90: 3535-3538. 578 
50) Shimamoto T, Tang Y, Naot Y, Nardi M, Brulet P, Bieberich CJ et al.  579 
Hematopoietic progenitor cell abnormalities in Hoxc-8 null mutant mice. 580 
Journal of Experimental Zoology 1999; 283: 186-193. 581 
51) Beuchle D, Struhl G, Muller J. Polycomb group proteins and heritable silencing of 582 
Drosophila Hox genes. Development 2001; 128: 993-1004. 583 
52)  Ernst P, Mabon M, Davidson AJ, Zon LI, Korsmeyer SJ. An Mll-Dependent Hox 584 
Program Drives Hematopoietic Progenitor Expansion. Current Biology 2004; 585 
14: 2063-2069. 586 
53) Jude CD, Climer L, Xu D, Artinger E, Fisher JK, Ernst P. Unique and 587 
Independent Roles for MLL in Adult Hematopoietic Stem Cells and 588 
Progenitors. Cell stem cell  2007; 1: 324-337. 589 
  27
54)  Davidson AJ, Zon LI. The caudal-related homeobox genes cdx1a and cdx4 act 590 
redundantly to regulate hox gene expression and the formation of putative 591 
hematopoietic stem cells during zebrafish embryogenesis. Developmental 592 
Biology 2006; 292: 506-518. 593 
55) Wang Y, Yabuuchi A, Mckinney-Freeman S, Ducharme DMK, Ray MK, 594 
Chawengsaksophak K et al. Cdx gene deficiency compromises embryonic 595 
hematopoiesis in the mouse. Proceedings of the National Academy of Sciences 596 
2008; 105: 7756-7761. 597 
56) Koo S, Huntly BJ, Wang Y, Chen J, Brumme K, Ball B et al. Cdx4 is dispensable 598 
for murine adult hematopoietic stem cells but promotes MLL-AF9-mediated 599 
leukemogenesis. Haematologica  2010; 95: 1642-1650. 600 
57)  Scholl C, Bansal D, Dohner K, Eiwen K, Huntly BJP, Lee, BH et al.  The 601 
homeobox gene CDX2 is aberrantly expressed in most cases of acute myeloid 602 
leukemia and promotes leukemogenesis. Journal of Clinical Investigation 603 
2007; 117: 1037-1048. 604 
58) Rawat VPS, Thoene S, Naidu VM, Arseni N, Heilmeier B, Metzeler K et al. 605 
Overexpression of CDX2 perturbs HOX gene expression in murine 606 
progenitors depending on its N-terminal domain and is closely correlated with 607 
deregulated HOX gene expression in human acute myeloid leukemia. Blood, 608 
2008; 111: 309-319. 609 
  28
59) Riedt T, Ebinger M, Salih HR, Tomiuk J, Handgretinger R, Kanz L et al. Aberrant 610 
expression of the homeobox gene CDX2 in pediatric acute lymphoblastic 611 
leukemia. Blood 2009; 113: 4049-4051. 612 
60) Faber J, Krivtsov AV, Stubbs MC, Wright R, Davis TN, Van Den Heuvel-Eibrink 613 
M et al. HOXA9 is required for survival in human MLL-rearranged acute 614 
leukemias. Blood  2009; 113: 2375-2385. 615 
61)  Hu YL, Passegué E, Fong S, Largman C, Lawrence HJ. Evidence that the Pim1 616 
kinase gene is a direct target of HOXA9. Blood 2007; 109: 4732-4738. 617 
62) Leverson JD, Koskinen PJ, Orrico FC, Rainio EM, Jalkanen KJ, Dash AB et al. 618 
Pim-1 Kinase and p100 Cooperate to Enhance c-Myb Activity. Molecular Cell 619 
1998; 2: 417-425. 620 
63) Hess JL, Bittner CB, Zeisig DT, Bach C, Fuchs U, Borkhardt A et al. c-Myb is an 621 
essential downstream target for homeobox-mediated transformation of 622 
hematopoietic cells. Blood  2006; 108: 297-304. 623 
64) Nagel S, Venturini L, Marquez V, Meyer C, Kaufmann M, Scherr M et al. 624 
Polycomb repressor complex 2 regulates HOXA9 and HOXA10, activating 625 
ID2 in NK/T-cell lines. Molecular Cancer 2010; 9: 151. 626 
65) Bei L, Lu Y, Eklund EA. HOXA9 Activates Transcription of the Gene Encoding 627 
gp91Phox during Myeloid Differentiation. Journal of Biological Chemistry 628 
2005; 280: 12359-12370. 629 
  29
66) Gwin K, Frank E, Bossou A, Medina KL. Hoxa9 Regulates Flt3 in 630 
Lymphohematopoietic Progenitors. The Journal of Immunology 2010; 185: 631 
6572-6583. 632 
67) Hu YL, Fong S, Ferrell C, Largman C, Shen WF. HOXA9 Modulates Its 633 
Oncogenic Partner Meis1 To Influence Normal Hematopoiesis. Molecular and 634 
Cellular Biology 2009; 29: 5181-5192. 635 
68) Huang Y, Sitwala K, Bronstein J, Sanders D, Dandekar M, Collins C et al. 636 
Identification and characterization of Hoxa9 binding sites in hematopoietic 637 
cells. Blood  2012; 119: 388-398. 638 
69) Takeda A, Goolsby C, Yaseen NR. NUP98-HOXA9 Induces Long-term 639 
Proliferation and Blocks Differentiation of Primary Human CD34+ 640 
Hematopoietic Cells. Cancer Research 2006; 66: 6628-6637. 641 
70)  Magnusson M, Brun ACM, Miyake N, Larsson J, Ehinger M, Bjornsson JM, et 642 
al. HOXA10 is a critical regulator for hematopoietic stem cells and 643 
erythroid/megakaryocyte development. Blood  2007; 109: 3687-3696. 644 
71) Shah CA, Bei L, Wang H, Platanias LC, Eklund EA. HoxA10 Protein Regulates 645 
Transcription of Gene Encoding Fibroblast Growth Factor 2 (FGF2) in 646 
Myeloid Cells. Journal of Biological Chemistry 2012; 287: 18230-18248. 647 
72) Shah CA, Wang H, Bei L, Platanias LC, Eklund EA. HoxA10 Regulates 648 
Transcription of the Gene Encoding Transforming Growth Factor β2 (TGFβ2) 649 
in Myeloid Cells. Journal of Biological Chemistry 2011; 286: 3161-3176. 650 
  30
73) Bei L, Lu Y, Bellis SL, Zhou W, Horvath E, Eklund EA. Identification of a 651 
HoxA10 Activation Domain Necessary for Transcription of the Gene 652 
Encoding β3 Integrin during Myeloid Differentiation. Journal of Biological 653 
Chemistry 2007; 282: 16846-16859. 654 
74) Wang H, Lu Y, Huang W, Papoutsakis ET, Fuhrken P, Eklund EA. HoxA10 655 
Activates Transcription of the Gene Encoding Mitogen-activated Protein 656 
Kinase Phosphatase 2 (Mkp2) in Myeloid Cells. Journal of Biological 657 
Chemistry 2007; 282: 16164-16176. 658 
75) Bei L, Huang W, Wang H, Shah C, Horvath E, Eklund E. HoxA10 Activates 659 
CDX4 Transcription and Cdx4 Activates HOXA10 Transcription in Myeloid 660 
Cells. Journal of Biological Chemistry 2011; 286: 19047-19064. 661 
76) Bromleigh VC, Freedman LP. p21 is a transcriptional target of HOXA10 in 662 
differentiating myelomonocytic cells. Genes & Development 2000; 14: 2581-663 
2586. 664 
77) Eklund EA, Jalava A, Kakar R. Tyrosine Phosphorylation of HoxA10 Decreases 665 
DNA Binding and Transcriptional Repression during Interferon γ-induced 666 
Differentiation of Myeloid Leukemia Cell Lines. Journal of Biological 667 
Chemistry 2000; 275: 20117-20126. 668 
78) Palmqvist L, Pineault N, Wasslavik C, Humphries RK. Candidate Genes for 669 
Expansion and Transformation of Hematopoietic Stem Cells by NUP98-HOX 670 
Fusion Genes. PLoS ONE 2007; 2: e768. 671 
  31
79)  Lee HM, Zhang H, Schulz V, Tuck DP, Forget BG. Downstream targets of 672 
HOXB4 in a cell line model of primitive hematopoietic progenitor cells. Blood 673 
2010; 116: 720-730. 674 
 80) Oshima M, Endoh M, Endo TA, Toyoda T, Nakajima-Takagi Y, Sugiyama F et 675 
al. Genome-wide analysis of target genes regulated by HoxB4 in 676 
hematopoietic stem and progenitor cells developing from embryonic stem 677 
cells. Blood  2011; 117: e142-e150. 678 
81) Fan R, Bonde S, Gao P, Sotomayor B, Chen C, Mouw T et al. Dynamic HoxB4 679 
regulatory network during embryonic stem cell differentiation to 680 
hematopoietic cells. Blood 2012; 119: e139-e147. 681 
82)  Pan Q, Simpson R. Antisense knockout of HOXB4 blocks 1,25-682 
dihydroxyvitamin D3 inhibition of c-myc expression. Journal of 683 
Endocrinology 2001; 169: 153-159. 684 
83) Satoh Y, Matsumura I, Tanaka H, Ezoe S, Sugahara H, Mizuki M et al. Roles for 685 
c-Myc in Self-renewal of Hematopoietic Stem Cells. Journal of Biological 686 
Chemistry 2004; 279: 24986-24993. 687 
84) Krosl J, Sauvageau G. AP-1 complex is effector of Hox-induced cellular 688 
proliferation and transformation. Oncogene 2000; 19: 5134-5141. 689 
85)  Nakamura T, Largaespada DA, Lee MP, Johnson LA, Ohyashiki K, Toyama K et 690 
al.  Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome 691 
  32
translocation t(7;11)(p15;p15) in human myeloid leukaemia. Nat Genet 1996; 692 
12: 154-158. 693 
86) Borrow J, Shearman AM, Stanton VP, Becher R, Collins T, Williams AJ et al.  694 
The t(7;11)(p15;p15) translocation in acute myeloid leukaemia fuses the genes 695 
for nucleoporin NUP96 and class I homeoprotein HOXA9. Nat Genet 1996; 696 
12: 159-167. 697 
87)  Fujino T, Suzuki A, Ito Y, Ohyashiki K, Hatano Y, Miura I et al. Single-698 
translocation and double-chimeric transcripts: detection of NUP98-HOXA9 in 699 
myeloid leukemias withHOXA11 or HOXA13 breaks of the chromosomal 700 
translocation t(7;11)(p15;p15). Blood  2002; 99: 1428-1433. 701 
88) Suzuki A, Ito Y, Sashida G, Honda S, Katagiri T, Fujino T et al. t(7;11)(p15;p15) 702 
chronic myeloid leukaemia developed into blastic transformation showing a 703 
novel NUP98/HOXA11 fusion. British Journal of Haematology 2002; 116: 704 
170-172. 705 
89)  Raza-Egilmez SZ, Jani-Sait SN, Grossi M, Higgins MJ, Shows TB, Aplan PD. 706 
NUP98-HOXD13 Gene Fusion in Therapy-related Acute Myelogenous 707 
Leukemia. Cancer Research 1998; 58: 4269-4273. 708 
90) Taketani T, Taki T, Shibuya N, Ito E, Kitazawa J, Terui K, Hayashi Y. The 709 
HOXD11 gene is fused to the NUP98 gene in acute myeloid leukemia with 710 
t(2;11)(q31;p15). Cancer Research 2002; 62: 33-37. 711 
  33
91) Taketani T, Taki T, Shibuya N, Kikuchi A, Hanada R, Hayashi Y. Novel NUP98-712 
HOXC11 fusion gene resulted from a chromosomal break within exon 1 of 713 
HOXC11 in acute myeloid leukemia with t(11;12)(p15;q13). Cancer Research 714 
2002; 62: 4571-4574. 715 
92) Pineault N, Abramovich C, Ohta H, Humphries RK. Differential and Common 716 
Leukemogenic Potentials of Multiple NUP98-Hox Fusion Proteins Alone or 717 
with Meis1. Mol Cell Biol 2004; 24: 1907-1917. 718 
93)  Palmqvist L, Argiropoulos B, Pineault N, Abramovich C, Sly LM, Krystal G et 719 
al. The Flt3 receptor tyrosine kinase collaborates with NUP98-HOX fusions in 720 
acute myeloid leukemia. Blood  2006; 108: 1030-1036. 721 
 94) Kroon E, Thorsteinsdottir U, Mayotte N, Nakamura T, Sauvageau G. NUP98-722 
HOXA9 expression in hemopoietic stem cells induces chronic and acute 723 
myeloid leukemias in mice. EMBO Journal 2001; 20: 350-361. 724 
 95) Pineault N, Buske C, Feuring-Buske M, Abramovich C, Rosten P, Hogge DE et 725 
al. Induction of acute myeloid leukemia in mice by the human leukemia-726 
specific fusion gene NUP98-HOXD13 in concert with Meis1. Blood 2003; 727 
101: 4529-4538. 728 
96) Tosic N, Stojiljkovic M, Colovic N, Colovic M, Pavlovic S. Acute myeloid 729 
leukemia with NUP98-HOXC13 fusion and FLT3 internal tandem duplication 730 
mutation: case report and literature review. Cancer Genetics and Cytogenetics 731 
2009; 193: 98-103. 732 
  34
97) Slany RK. The molecular biology of mixed lineage leukemia. Haematologica-the 733 
Hematology Journal 2009; 94: 984-993. 734 
98) Meyer C, Kowarz E, Hofmann J, Renneville A, Zuna J, Trka J et al. New insights 735 
to the MLL recombinome of acute leukemias. Leukemia 2009; 23: 1490-1499. 736 
99) Milne TA, Briggs SD, Brock HW, Martin ME, Gibbs D, Allis CD et al.  MLL 737 
Targets SET Domain Methyltransferase Activity to Hox Gene Promoters. 738 
Molecular Cell  2002; 10: 1107-1117. 739 
100) Abdul-Nabi AM, Yassin ER, Varghese N, Deshmukh H, Yaseen NR.  In vitro 740 
transformation of primary human CD34+ cells by AML fusion oncogenes: 741 
early gene expression profiling reveals possible drug target in AML. PLoS 742 
ONE 2010; 5: e12464. 743 
101) Ayton PM, Cleary ML.  Transformation of myeloid progenitors by MLL 744 
oncoproteins is dependent on Hoxa7 and Hoxa9. Genes & Development 2003; 745 
17: 2298-2307. 746 
102) Bansal D, Scholl C, Frohling S, Mcdowell E, Lee BH, Dohner K et al. Cdx4 747 
dysregulates Hox gene expression and generates acute myeloid leukemia alone 748 
and in cooperation with Meis1a in a murine model. Proceedings of the 749 
National Academy of Sciences of the United States of America  2006; 103: 750 
16924-16929. 751 
103) Bansal D, Scholl C, Fröhling S, Mcdowell E, Lee BH, Döhner K et al. Cdx4 752 
dysregulates Hox gene expression and generates acute myeloid leukemia alone 753 
  35
and in cooperation with Meis1a in a murine model. Proceedings of the 754 
National Academy of Sciences  2006; 103: 16924-16929. 755 
104) Rau R, Brown P.  Nucleophosmin (NPM1) mutations in adult and childhood 756 
acute myeloid leukaemia: towards definition of a new leukaemia entity. 757 
Hematological Oncology 2009; 27: 171-181. 758 
105) Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L et al. 759 
Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal 760 
Karyotype. New England Journal of Medicine 2005: 352: 254-266. 761 
106) Thiede C, Koch S, Creutzig E, Steudel C, Lllmer T, Schiach M, Ehninger G. 762 
Prevelance and prognostic impact of NPM1 mutations in 1485 adult patients 763 
with acute myeloid leukemia (AML). Blood 206; 107: 4011:4020. 764 
107) Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L, 765 
Dohner H. Mutations and Treatment Outcome in  Cytogenetically Normal 766 
Acute Myeloid Leukemia. New Journal of Medicine 2008; 358: 1909-1918. 767 
108)  Brown P, Mcintyre E, Rau R, Meshinchi S, Lacayo N, Dahl G et al.  The 768 
incidence and clinical significance of nucleophosmin mutations in childhood 769 
AML. Blood 2007; 110: 979-985. 770 
109) Hollink IHIM, Zwaan CM, Zimmermann M, Arentsen-Peters TCJM, Pieters R, 771 
Cloos J et al.  Favorable prognostic impact of NPM1 gene mutations in 772 
childhood acute myeloid leukemia, with emphasis on cytogenetically normal 773 
AML. Leukemia 2009; 23: 262-270. 774 
  36
110). Falini B, Bolli N, Liso A, Martelli MP, Mannucci R, Pileri S, Nicoletti I  775 
Altered nucleophosmin transport in acute myeloid leukaemia with mutated 776 
NPM1: molecular basis and clinical implications. Leukemia  2009; 23: 1731-777 
1743. 778 
111) Mullighan CG, Kennedy A, Zhou X, Radtke I, Phillips LA, Shurtleff SA, 779 
Downing JR  Pediatric acute myeloid leukemia with NPM1 mutations is 780 
characterized by a gene expression profile with dysregulated HOX gene 781 
expression distinct from MLL-rearranged leukemias. Leukemia 2007; 21: 782 
2000-2009. 783 
112) Vassiliou GS, Cooper JL, Rad R, Li J, Rice S, Uren A et al. Mutant 784 
nucleophosmin and cooperating pathways drive leukemia initiation and 785 
progression in mice. Nat Genet  2011; 43: 470-475. 786 
113) Ferrando AA, Armstrong SA, Neuberg DS, Sallan SE, Silverman LB, 787 
Korsmeyer SJ et al. Gene expression signatures in MLL-rearranged T-lineage 788 
and B-precursor acute leukemias: dominance of HOX dysregulation. Blood 789 
2003; 102: 262-268. 790 
114)  Rozovskaia T, Feinstein E, Mor O, Foa R, Blechman J, Nakamura T et al. 791 
Upregulation of Meis1 and HoxA9 in acute lymphocytic leukemias with the 792 
t(4 : 11) abnormality. Oncogene 2001; 20: 874-878. 793 
115) Krivtsov AV, Feng Z, Lemieux ME, Faber J, Vempati S, Sinha AU et al.  794 
H3K79 Methylation Profiles Define Murine and Human MLL-AF4 795 
Leukemias. Cancer Cell 2008; 14: 355-368. 796 
  37
116) Zangrando A, Dell'orto MC, Kronnie GT, Basso G.  MLL rearrangements in 797 
pediatric acute lymphoblastic and myeloblastic leukemias: MLL specific and 798 
lineage specific signatures. Bmc Medical Genomics 2009; 2. 799 
117) Dik WA, Brahim W, Braun C, Asnafi V, Dastugue N, Bernard OA et al. CALM-800 
AF10+ T-ALL expression profiles are characterized by overexpression of 801 
HOXA and BMI1 oncogenes. Leukemia  2005; 19: 1948-1957. 802 
118)  Soulier J, Clappier E, Cayuela JM, Regnault A, García-Peydró M, Dombret H et 803 
al. HOXA genes are included in genetic and biologic networks defining 804 
human acute T-cell leukemia (T-ALL). Blood 2005; 106: 274-286. 805 
119) Speleman F, Cauwelier B, Dastugue N, Cools J, Verhasselt B, Poppe B et al. A 806 
new recurrent inversion, inv(7)(p15q34), leads to transcriptional activation of 807 
HOXA10 and HOXA11 in a subset of T-cell acute lymphoblastic leukemias. 808 
Leukemia 2005; 19: 358-366. 809 
120) Thoene S, Rawat VPS, Heilmeier B, Hoster E, Metzeler KH, Herold T et al. The 810 
homeobox gene CDX2 is aberrantly expressed and associated with an inferior 811 
prognosis in patients with acute lymphoblastic leukemia. Leukemia 2009; 23: 812 
649-655. 813 
121) Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP et al. 814 
Molecular Classification of Cancer: Class Discovery and Class Prediction by 815 
Gene Expression Monitoring. Science 1999; 286: 531-537. 816 
  38
122) Andreeff M, Ruvolo V, Gadgil S, Zeng C, Coombes K, Chen W et al. HOX 817 
expression patterns identify a common signature for favorable AML. 818 
Leukemia  2008; 22: 2041-2047. 819 
123) Zangenberg M, Grubach L, Aggerholm A, Silkjaer T, Juhl-Christensen C, 820 
Nyvold CG et al. The combined expression of HOXA4 and MEIS1 is an 821 
independent prognostic factor in patients with AML. Eur J Haematol  2009; 822 
83: 439-48. 823 
124)  Daniels TR, Neacato II, Rodriguez JA, Pandha HS, Morgan R, Penichet ML  824 
Disruption of HOX activity leads to cell death that can be enhanced by the 825 
interference of iron uptake in malignant B cells. Leukemia 2010; 24: 1555-826 
1565. 827 
125) Morgan R, Pirard P, Shears L, Sohal S, Pettengell R, Pandha H. Antagonism of 828 
HOX/PBX dimer formation blocks the in vivo proliferation of melanoma. 829 
Cancer Res 2007; 67: 5806 - 5813. 830 
126)  Plowright L, Harrington KJ, Pandha HS, Morgan R  HOX transcription factors 831 
are potential therapeutic targets in non-small-cell lung cancer (targeting HOX 832 
genes in lung cancer). Br J Cancer 2009; 100: 470-475. 833 
127) Shears L, Plowright L, Harrington K, Pandha H, Morgan R.  Disrupting the 834 
interaction between HOX and PBX causes necrotic and apoptotic cell death in 835 
the renal cancer lines CaKi-2 and 769-P. J Urol 2008; 180: N2196 - 2201.   836 
  39
128) Morgan R, Plowright L, Harrington K, Michael A, Pandha H. Targeting HOX 837 
and PBX transcription factors in ovarian cancer. BMC Cancer  2010; 10: 89. 838 
129) Espinosa AV, Shinohara M, Porchia LM, Chung YJ, Mccarty S, Saji M, Ringel 839 
MD  Regulator of calcineurin 1 modulates cancer cell migration in vitro. 840 
Clinical & Experimental Metastasis 2009; 26: 517-526. 841 
 842 
 843 
 844 
 845 
 846 
 847 
 848 
 849 
 850 
 851 
 852 
 853 
  40
 Figure Legends 854 
Figure 1: A schematic structure of clustered HOX genes. The 39 HOX genes are 855 
located on four different chromosomes. Homology of human HOX genes HOX-C 856 
to Drosophila HOM-C genes is shown by colours. Blank squares show missing 857 
genes.   858 
Figure 2: Structures of AbdB HOX, NUP98 and the predictive fusion protein 859 
NUP98-HOX. A) A general structure of AbdB HOX (9-13) proteins that have been 860 
reported to fuse with NUP98. B) Structure of normal NUP98 protein. C) Structure 861 
of predictive NUP98-HOX fusion protein. This fusion eliminates MD and RBD 862 
from AbdB and NUP98, respectively. The arrows represent the breakpoints. MD: 863 
MEIS domain, PM: Pbx motif, H: hexapeptide, HD: homeodomain, FG: 864 
phenylalanine-glycine, GLEBS: gle2p-binding-like motif, RBD: RNA binding 865 
domain. 866 
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Table 2: A summary of mammalian HOX target genes.  868 
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Table 1: HOX gene studies 
HOX gene Gain of function Loss of function Species References 
HOXA5 ↑myeloid progenitors and 
block erythroid 
differentiation. 
↑erythroid progenitors and 
↓myelomonocytic cells.  
Human 33,34  
Hoxa7  ↓ MEP, reticulocytosis and 
thrombocytopenia. 
Mouse 46 
Hoxa9 ↑HSCs expansion and 
myeloid progenitor 
proliferation. 
Block erythroid 
differentiation and ↓ pre B-
cell differentiation. 
↓↓CMP, GMP, CLP, lymphoid 
precursors, repopulating ability 
and ↓ spleen cellularity and 
size.  
Mouse 36,37,46,47
HOXA10 ↑↑ blast cells and 
myelopoiesis, ↓ B cell 
differentiation and block 
erythroid differentiation. 
 Human 35 
Hoxb3 Block B and T cell 
differentiation and a delay 
in myeloid precursor 
proliferation. 
↓↓ B cell progenitors and bone 
marrow cellularity.  
Mouse 31,44 
HOXB4/ 
Hoxb4 
↑↑ HSCs expansion.  ↓↓ Hematopoietic organs 
cellularity and size, ↓ HSCs 
and HPs and ↑ Hoxb genes. 
Human / Mouse 38,39,42,43
Hoxb3/b4  ↓↓ HSCs and HPs.   Mouse 45 
Hoxb6 ↑HSCs expansion and 
myeloid precursor 
proliferation. 
 ↓ erythropoiesis and 
lymphopoiesis.  
 ↑ Early erythroid progenitors. Mouse 30,48 
Hoxc3  ↓ erythroid progenitors.  Mouse 49 
HOXC4 ↑ early and committed 
myeloid and erythroid 
progenitors. 
 Human 32 
Hoxc8  ↓↓ erythroid, granulocyte and 
macrophage colony formation 
potential.  
Mouse 50 
 
 
 
 
 
 
Table 2: A summary of mammalian HOX target genes.  
HOX protein Targets of transcriptional activation Targets of transcriptional 
repression 
Species References 
HOXA9/ Hoxa9 Pim1, ID2, CYBB, HOXA7, HOXA10, 
PBX3 and MEIS1/ Flt3, Cerb1, Pknox1, 
Camk2d, Cdk6, Erg, Etv6, Foxp1, Gfi1, 
Kit, Lck, Lmo2, Myb and Sox4.  
BIM/ Itfi1, Tlr4, Ccl3, Ccl4, 
Csf2rb, Ifngr1, Runx1, 
Cd28, and Cd33. 
Human/ Mouse 60,61,64-68
Hoxa9-Meis1 c-Myb.  Mouse 63
NUP98-HOXA9 HOXA7, HOXA9, MEIS1, PBX3, EVI1, 
MEF2C, FLT3 and KIT. 
 Human 69
HOXA10/ 
Hoxa10 
P21 and DUSP4/ Itgb3, Hlf, Tgfβ2, Fgf2, 
Hoxa5, and Cdx4. 
CYBB/ Gata1. Human /  Mouse 70,73-77
Nup98-Hoxa10 Flt3, Prnp, Hlf and Jag2.   Mouse 78
HOXB4/ Hoxb4 Meis1, Dntt, Hlf, Sox4, Runx2, and C-myc/ 
Hoxb2, Hoxb3, Hoxb5, Fra-1 and JunB.    
B220 and  HMBS/ C-MYC. Human / Mouse 42,79,82-84
 
 
 
 
